Morgan Stanley has cut its price target for Structure Therapeutics from $126 to $117 but still rates it as 'Outperform.

Nov 13, 2026, 6:07 PM ETOpinionRead the original at marketscreener.com

Neutral

Morgan Stanley cut its target to $117 from $126 but kept its Outperform rating. Those mixed views report no change in Structure Therapeutics' business outlook.

GPCR · Structure Therapeutics

AI read · Neutral

The AI's read

This is Morgan Stanley's view, not a report of a change in Structure Therapeutics' business. The lower target points one way, but keeping the Outperform rating points the other. The story gives no new company results or trial news.

Get alerts for GPCR

Follow Structure Therapeutics (GPCR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for GPCR

Free on the App Store and Google Play, or on the web.